Aarti Pharmalabs Ltd

- No mention of any current or planned fundraising through debt or equity in the transcript. - The company focuses on internal cash flows and ongoing projects for growth, including capacity expansions and new plants like Atali. - Discussions highlight operational growth, cost savings (e.g., from solar plant), and capacity ramp-ups without reference to raising new external capital. - The company appears confident in achieving growth targets with existing resources and investments.

- Brownfield expansion to increase Xanthine derivatives capacity from 5,000 MT to 9,000 MT per annum; commissioning to be done in a phased manner across H2 FY '26. - Greenfield project at Atali, Gujarat nearing completion; mechanical completion of Phase-1 achieved; commercial production to commence towards end of Q2 FY '26. - Additional caffeine capacity addition planned in second half of this year. - Next year to see higher capacities enabling production of more products. - Ongoing efforts on de-bottlenecking of API lines and capacity additions to support growth in base business. - Investments in enhancing CDMO capabilities including cyanation, continuous manufacturing, cryogenic reactions, hydrogenation, and HPAPIs (anti-cancer products). - Future expansion blocks planned every two years subject to occupancy levels. Overall, these capex plans aim to drive growth in CDMO, Xanthine, and API segments while improving margins and supporting long-term strategic objectives.

- CDMO segment expected to grow 30%-40% this year, aiming for Rs. 800-1,000 crores revenue in 3-4 years (Page 17, 9). - Overall CDMO growth target of Rs. 800-1,000 crores by FY '29 (Page 9). - Xanthine business capacity expanding from 5,000 to 9,000 tons, targeting Rs. 1,000+ crores revenue in 2-3 years with 80%-90% utilization and 50% of sales to beverages and regulated customers (Pages 10-11). - API segment expected to grow 10%-15% this year and maintain reasonable growth levels, with capacity expansions and de-bottlenecking underway (Page 17). - Additional capacities, such as Atali plant, to drive growth starting H2 FY ’26 onwards with risk-mitigated multi-site manufacturing capabilities (Page 15, 17). - EBITDA growth expected to align with topline expansion, with CDMO margins highest among segments (Page 15).

- CDMO segment is expected to grow at 30%-40% annually this year, aiming for Rs. 800-1000 crore revenue in 3-4 years. - Overall EBITDA growth guidance maintained at 12%-15% year-on-year, supported by standalone 14% EBITDA increase in Q1 FY '26. - Margins expected to remain stable with possible ±2%-3% variation; CDMO segment has the highest margin profile. - Xanthine segment capacity to increase from 5,000 to 9,000 tons, targeting Rs. 1,000 crore topline in 2-3 years with better product mix and pricing. - API segment expected to grow at 10%-15%, supported by de-bottlenecking and new capacities coming online in H2 FY '26. - New manufacturing facilities, including Atali plant, expected to contribute incremental revenues and cost savings, boosting earnings. - Earnings may exhibit quarterly variability due to nature of CDMO invoicing and project stages. Overall long-term growth remains confident.

- The company currently has an order book guiding CDMO sales growth of 35%-40% for the year. - There are 60 ongoing active CDMO projects: 33 in commercial stages and 27 in different stages of development. - The management is confident about achieving Rs. 800 crore to Rs. 1,000 crore revenue from the CDMO segment by FY '28 or FY '29, a 3-4 year timeline. - Growth drivers include both existing commercial molecules and a robust underdevelopment pipeline. - The final commercial success depends on customer approvals and market performance of the products. - The company has seeded about 60 projects and is actively working on multiple stages of processing.